tbuckley/cabot-search huggingface dataset:
P-261 Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)
Authors: A. Cleton, I. Sturm, Z. Jirakova Trnkova, J. Grevel, S. Fiala-Buskies, J. Lettieri
Journal: Annals of Oncology (2015)
PTU-009 Endoscopic Resection of Caecal Lesions ≥10 MM: Incomplete Resection and Complication Rate: Abstract PTU-009 Table 1
Authors: C Lam, S Sansone, K Ragunath, A Parra-Blanco
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic resection (ER) of caecal lesions remains technically challenging due to instability of the scope, bowel preparation and thinner bowel wall. Such limitations can affect completeness of ER. Currently there are very few data on endoscopic outcomes following ER of caecal lesions <b>≥</b>10 mm. Our aim was to assess completeness and complication of ER. <h3>Methods</h3> Retrospective data was collected between 2011–2015 from documentation system ENDOBASE for all patients who had caecal ER. All lesions <b>≥</b>10 mm were included. Morphology was categorised as per Paris classification. The following variables were recorded: lesion size and shape, type of ER (en bloc vs piecemeal), completeness of ER, histology, early complications, endoscopic follow up and remnant neoplasia on follow up. <h3>Results</h3> Mean (SD). A total of 111 caecal resections were performed. See table 1 for demographic details. Average lesion size was 17.2 (8.3) mm; Ip 15.0 (7.0), Is 14.7 (4.6), non-polypoid lesion 17.9 (8.8) mm. En bloc resection was achieved in 63%. In lesions &lt;20 mm, en bloc resection was 82% vs 26% in ≥20 mm lesion (p &lt; 0.001). Complete endoscopic resection was in 93% (97% in lesions &lt;20 mm vs 31% in ≥20 mm; p &lt; 0.02). However definite histological confirmation of complete resection was in 23%. There was no early major complication. 68% of these lesions showed low-grade dysplasia, 7% high grade dysplasia, 5% serrated lesions and 21% were hyperplastic. Only 58 of 111 were followed up with colonoscopy in 3–36 months. In this group, 17% had endoscopic recurrent neoplasia on follow up. Average follow up was 7 months. Recurrence was treated with either or a combination of repeat EMR (42%), APC (17%) or biopsy forceps (42%). On average, it took 3.5 colonoscopies to achieve complete clearance. In patients with recurrent caecal lesions, there was no difference if their first ER was either by piecemeal or en bloc resection (p = 0.97). Recurrence was detected in 9% for all completely resected caecal lesions and 11% recurrence in ≥20 mm lesions. Recurrence was detected in all incomplete resected lesions (n = 5). 1 additional patient had remnant tissue detected only on biopsy on normal looking scar. The only variable associated with remnant neoplasia was an incomplete resection. <h3>Conclusion</h3> Remnant tissue post ER was similar to the UK national guidelines for colorectal polyps.<sup>1</sup> Endoscopic resection of caecal lesions remains a challenge. Incomplete resection lesion invariably has remnant neoplasia on follow up. Strategies such as ESD/hybrid EMR should be considered. <h3>Reference</h3> 1 Rutter <i>et al</i>. doi:10.1136/gutjl-2015-309576 <h3>Disclosure of Interest</h3> None Declared
Healthcare comes to standstill in east Aleppo as last hospitals are destroyed
Authors: Nayanah Siva
Journal: BMJ (2016)

Repeated attacks by government and allied forces in east Aleppo have left it with no functioning hospitals, Fadi Al Dari, country director of the charity Hand in Hand for Syria, has confirmed.

Since the war started in Syria in 2011 there have been 382 attacks on 269 separate medical facilities in the country, and 757 medical personnel have died, said the US based humanitarian organisation Physicians for Human Rights.1

Deliberate and strategic attacks on healthcare facilities in Aleppo were condemned by humanitarian doctors at the World Extreme Medicine Conference in Edinburgh last week. Saleyha Ahsan, a filmmaker and emergency medicine doctor, spoke …
Host Genetic Variation in the Cell Cycle and NF-κB Pathways and Overall Survival in Mantle Cell Lymphoma.
Authors: Thomas M. Habermann, Matthew J. Maurer, Sophia S. Wang, Lindsay M. Morton, Charles F. Lynch, Patricia Hartge, Wendy Cozen, Richard K. Severson, Davis Scott, David A. Watson, Stephen J. Chanock, Nathanial Rothman, James R. Cerhan
Journal: Blood (2007)
Prospective Phase II Study of Pre-Administration of Rabbit Antithymocyte Globulin (rATG, Thymoglobulin ®) to Maximize Early T-Cell Chimerism Following Allogeneic Reduced Intensity Conditioning Transplant (RICT) through Differential in-Vivo Depletion of Recipient Versus Donor T-Cells.
Authors: Melissa Sanacore, Stacey Brown, Candice G Roth, Ming Zhang, Pauline Smith, H. Kent Holland, Lawrence E. Morris, Scott R. Solomon, Asad Bashey
Journal: Blood (2009)
Inducible Levels of Gelatinase B/Matrix Metalloproteinase-9 Gene Expression in Monocytes Are Associated with Marrow Cellularity in Myelodysplastic Syndrome (MDS).
Authors: Mineo Iwata, Manoj Pillai, H. Joachim Deeg, Ghislain Opdenakker, Beverly Torok-Storb
Journal: Blood (2005)
FRI0083 Factors Associated with The Need for Biological Therapies in Patients with Rheumatoid Arthritis
Authors: M. Cuadros, J.L. Andreu, I. Millan, M. Bascuas, C. Ramos, M. Espinosa, B.J. Flores, J. Campos, J. Sanz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to an irreversible destruction of diarthrodial joints. Early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs) are considered essential in order to achieve an optimal suppression of disease activity and prevent structural and functional deterioration. Biological therapy (BT) is the second-line treatment in case of inadequate response to DMARDs. BT has excellent safety and efficacy profiles. However, its economic burden is high. <h3>Objectives</h3> The goal of our study was to identify clinical, epidemiological and analytical characteristics, as well as the delay of diagnosis, DMARD treatment, and inflammatory activity, associated with the need to initiate BT in RA patients. <h3>Methods</h3> This is a single-center case-control study. We included patients who were diagnosed with RA from January 1, 2000, fulfilling the 2010 ACR/EULAR criteria. The main outcome (dependent variable) was the need for a first biological drug. The independent variables were time to diagnosis, time to treatment with the first DMARD, time to clinical remission, time to low activity, age, gender, number of swollen joints (NSJ) and tender joints (NTJ) at the time of diagnosis, positivity of RF and ACPA, CRP, ESR, radiologic erosions, smoking, body mass index, education level, and job status. The study was approved by the research ethical committee of our center. Descriptive statistics was used to present the results; chi-square test, Student t test, and Mann-Whitney U test were used to define statistical significance in the univariate analysis; and logistic regression for multivariate analysis. A <i>P</i>-value &lt;0.05 was predefined as statistical significance. Statistical analyses were performed by using the SPSS v14.0. <h3>Results</h3> One hundred and thirty-nine patients were included (mean age 53 years; 82% women; 83% white; 82% RF+; 74% ACPA+). Sixty-one patients (44%) had received BT. The univariate analysis demonstrated significant association between the need for BT and NTJ (p&lt;0,001), NSJ (p=0,004), ESR (p=0,026), time to low disease activity (p&lt;0,001) and time to remission (p&lt;0,001). The multivariate logistic regression indicated that the NTJ at diagnosis, the time to low activity and the time to remission were independently associated with the need for BT during follow-up. <h3>Conclusions</h3> In RA patients, the number of tender joints at the time of diagnosis and the time to low disease activity and clinical remission are associated with the need for BT during the course of the disease. <h3>Disclosure of Interest</h3> None declared
SP0171 EULAR/ACR Guidelines for PMR – The Updated Evidence
Authors: C. Dejaco
Journal: Annals of the Rheumatic Diseases (2016)

Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in older people after rheumatoid arthritis. According to the 2015 EULAR-ACR recommendations for the management of PMR, oral glucocorticoids (GC) are the first choice treatment for this condition. It is recommended to choose the minimum effective GC dose within a range of 12.5–25mg prednisone equivalent daily as the initial therapy and to gradually taper the dose, based on regular monitoring of patient disease activity, laboratory markers and adverse events. An early introduction of methotrexate (MTX) in addition to GCs may be considered, particularly in patients at high risk for relapse and/or prolonged therapy as well as in cases with risk factors, co-morbidities, and/or concomitant medications where GC related adverse events are more likely to occur. For other conventional disease modifying anti-rheumatic drugs (DMARDs), a specific recommendation was not possible due to the absence of good evidence. Among biological agents, infliximab and etanercept failed its primary endpoint in randomized controlled trials, and consequently, a strong recommendation against the use of TNF-a blocking agents was made. Since the publication of 2015 EULAR-ACR recommendations, observational studies and small, randomized trials reported promising results about the effective use of interleukin (IL)-6 blocking agents in PMR. If these preliminary data are confirmed by larger randomized controlled trials, IL-6 blockade might become an important therapeutic option for PMR patients in future. In this session, we will discuss current evidence on the role of steroid sparing agents in the treatment of PMR including the promising new results from studies on IL-6 blockade. <h3>Disclosure of Interest</h3> C. Dejaco Grant/research support from: Pfizer, MSD, Consultant for: MSD, Pfizer, UCB, AbbVie, Roche, GSK, Novartis, Lilly, BMS, Celgene, Speakers bureau: MSD, Pfizer, UCB, AbbVie, Roche, GSK, Novartis, Lilly, BMS, Celgene, Merck, Signatis Pharma
Appropriate Management of Asymptomatic Hypertension
Authors: Candace D. McNaughton, Aaron Brody, Phillip D. Levy
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PWE-011 Is Ulcerative Colitis (UC) Managed Adequately in Primary Care?
Authors: D Aldulaimi, D Farmer, H Prasher, R Jazrawi
Journal: Gut (2016)

<h3>Introduction</h3> Once remission is induced, the majority of patients with mild to moderate UC are managed in primary care on long term 5 ASA maintenance therapy. Lack of adherence to therapy has significant implications for patients with an impact on the use of NHS resources. The aim was to assess the management of patients with mild to moderate UC on 5 ASA maintenance therapy in primary care. <h3>Methods</h3> All UC patients on 5 ASA therapy from 31 practices covering three CCGs in were identified and invited to attend a clinic at their practice. Disease location, activity (Walmsley Index), 5 ASA dose and frequency and adherence to therapy were recorded. <h3>Results</h3> 481 UC patients were identified, 212 reviewed and 158 patients (M:F = 99:59) fully assessed. Age (mean [range]; 60.6 [22–88 yrs.] yrs.). UC subclass (No [%]): proctitis 23 [14%]; distal colitis: 59 [39%]; pan colitis: 38 [24%]; UC unspecified:38 [23%]. 58% on Asacol; 30% on Pentasa and 9% on Mezavant respectively. Maintenance dose range 1–6.4 g/day; 29% were on lower than the recommended dose for their specific 5 ASA. 48 (31%) received other therapies (azathioprine, steroids or mesalazine enemas). Walmsley Index (mean 2.3) was ­ ≥4 in 27 patients (17%) indicating flare. 27 patients (17%) had symptoms and 39 (29%) had adherence issues. Several patients missed routine surveillance colonoscopy and blood tests. <h3>Conclusion</h3> UC is inadequately managed in primary care <h3>Disclosure of Interest</h3> D. Aldulaimi: None Declared, D. Farmer: None Declared, H. Prasher: None Declared, R. Jazrawi Conflict with: Dr R Jazrawi is medical Director of Dr Falk Pharma UK
Determination and regulation of body composition in elite athletes
Authors: Peter Sonksen
Journal: British Journal of Sports Medicine (2016)

In 2011, the International Association of Athletics Federations (IAAF) and IOC introduced a ‘hyperandrogenism’ rule that excluded women with a serum testosterone &gt;10 nmol/L from participating in elite sport. This rule was based on the false premise that the greater lean body mass in men was a consequence of their higher serum testosterone. This rule did not have scientific backing and the Court of Arbitration for Sport subsequently rescinded the rule following an appeal from an Indian athlete barred from the Commonwealth Games. This review covers the scientific knowledge about the development and regulation of body composition in humans but also considers the lessons learnt from evolution and breeding in animals. The importance of heredity has been documented in family and twin studies. The roles of growth hormone and sex steroids are reviewed. The Androgen Insensitivity Syndrome (AIS) is considered as a model of the role of testosterone in development of body composition and also as evidence of the importance of other factors carried on the Y-chromosome that are of prime importance but have been systematically ignored. Finally the key factors determining body composition are considered and placed in a suggested order of importance.
Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus
Authors: Monica Cusan, Naidu M. Vegi, Medhanie A. Mulaw, Shiva Bamezai, Lisa M. Kaiser, Aniruddha J. Deshpande, Philipp A. Greif, Leticia Quintanilla-Fend, Stefanie Göllner, Carsten Müller-Tidow, Keith R. Humphries, Scott A. Armstrong, Wolfgang Hiddemann, Michaela Feuring-Buske, Christian Buske
Journal: Blood (2016)
원저 : C형 간염 환자에 대한 Interferon alpha 치료 효과
Authors: 이헌주, 서정일, 박찬원 ( Heon Ju Lee), Jeong Ill Suh, Chan Won Park
Journal: Clinical and Molecular Hepatology (1996)

Background/Aims .' Hepatitis C virus(HCV) was known to most common etiologic agent of chronic liver disease in United states and Japan. Although hepatitis B virus(HBV) was well known to be a its major etiologic agent in Korea, it has been showed that HCV and HBV are associated with liver cirrhosis and hepatocellular carcinoma as major causative agent of chronic liver disease. Interferon alpha therapy is generally accepted as effective single agent for chronic hepatitis or to decrease the chronicity of acute hepatitis C. So, we evaluated the efficacy of interferon alpha in hepatitis C. Methods '. 46 patients who were positive for anti-HCV antibody and HCV RNA were included in this study. Liver biopsy was per formed on all patients and all of them were tested as negative for serum HBsAg, anti Hbe. Patients were divided into 2 groups . 30 patients received interferon therapy(treated group) and 16 patients received no therapy(untreated group). We compared the change of liver function test and HCV RNA before and after therapy between two groups. Treated group was subdivided into 5 groups according to response to interferon therapy '. Non-response, partial response, breakthrough, relapse and sustained response. Results . 1) The mean age and sex distribution were 49.9 year old, male 19, female 11 in treated group and 48.7 years, male 12, female 4 in untreated group. 2) The number of patients with acute hepatitis, chronic persistent hepatitis, chronic active hepatitis and liver cirrhosis were 1, 2, 23, 4 in treated group and 0, 1, 12, 3 in untreated group, respectively. 3) The mean follow up period was 1.7 year and 2.3 years in treated and untreated group, respectively. 4) The activity of serum ALT before and after therapy were 195+ 134.6 IU/L, 87.4+ 40.5 IU/L and 186.7+ 106.4 IU/L, 157+ 87.1 IU/L in treated and untreated group, respectively. Serum ALT after therapy in treated group was significantly lower than untreated group(P 0.05). 6) The case of negative conversion for HCV RNA in treated group was 12, but there was no case in untreated group. 7) Sex distribution of sustained response was 6(31% ) of 19 male, 6(54.5%) of 11 female and 12 patients(40.0%)(1 of 1 patients with acute hepatitis, 1 of 2 chronic persistent hepatitis, 10 of 23 chronic active heaptitis) included in sustained reponse, but any patients with liver cirrhosis had response. 8) Mean total dose and duration of interferon therapy was non-response 10353.6 million unit(MU)/5.8month(M), partial response 20025.06MU/6.4 M, breakthrough 36000.0MU/5.0M, relapse 11700.0MU/3.3M, sustained response 28100.0MU/6.6M, respectively. 9) 3 of 7 patients who were followed up over 1 year in sustained response and mean time to the relapse was 2.2 years. Conclusion '. Our results showed that interferon alpha therapy is effective in patients with hepatitis C and further study and attempts should be performed to augument the efficacy of interferon alpha for the treatment of hepatitis C.
THU0294 An International Consensus Exercise To Classify SLE Damage Items According To Their Likely Association with Steroids: Table 1.
Authors: J. Little, M. Lunt, B. Parker, I.N. Bruce
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Corticosteroids (CS) have been identified as a key factor associated with long term damage in systemic lupus erythematosus (SLE). The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) has been extensively validated and a previous analysis (Gladman et al J Rheumatol 2003;30:1955–9) suggested that SDI items can be grouped according to their likely association with CS. <h3>Objectives</h3> To generate international expert consensus opinion on which SDI items have an association with the use of CS. <h3>Methods</h3> We performed a Delphi exercise amongst SLICC members and associates. A survey requested expert opinions on how each SDI item was influenced by CS use on a Likert scale. The scale ranged from -3 to +3 where -3 = I believe that CS have a strong protective link with this item, 0 = I believe that CS have no effect on this item, +3 = I believe that CS have a strong causal link with this item. A second Delphi round presented each participant with their previous rating and the group median for that item, providing the opportunity for revision. A preliminary univariate analysis of CS exposure against damage was performed within the SLICC Inception Cohort to assess the appropriateness of these groupings and if any other items needed reclassifying. <h3>Results</h3> Of 43 members/associates, 36 respondents returned 26 complete forms (60.5%). All 26 completed the second round (100%) after which adequate consensus was reached. Four items (cataract, osteoporosis, avascular necrosis and diabetes mellitus) were assessed to be highly likely to be related to CS (median &amp; mode =3, Table 1). Ten other items were "probably"/"possibly" CS related by expert opinion. The remaining items were felt not to be associated with CS. The univariate analysis supported these groupings and identified a significant association between CS exposure and the muscle atrophy/weakness item (e.g. OR (95% CI) 6.81 (1.91–24.27) if on steroids for all of intervening follow up period c.f. some or none of the period). It was agreed that muscle atrophy/weakness should be reclassified into the 9definite association9 group. <h3>Conclusions</h3> A consensus exercise based on expert opinion and initial analysis in an international inception cohort has generated a preliminary classification of the 42 SDI items according to their likely association with CS. This classification system requires further validation but will facilitate studies examining the impact of CS exposure on SLE populations. <h3>Acknowledgement</h3> The Systemic Lupus International Collaborating Clinics (SLICC) acknowledge funding support of UCB Pharma for this study. <h3>Disclosure of Interest</h3> None declared
FRI0029 Human CD40l Deficiency Dysregulates The Macrophage Transcriptome Causing Functional Defects That Are Improved by Exogenous IFN-Gamma
Authors: O.C. Marques, L.F. Schimke Marques, T.A. Khan, E. Pinheiro Amaral, C.C. Barbosa Bomfim, O. Reis Junior, J.D.C. Correia Lima, C. Worm Weber, J. Fernandes Ferreira, F. Scancetti Tavares, M.R. D'Imperio Lima, M. Seelaender, V.L. Garcia Calich, J.A. Marzagão Barbuto, B. Tavares Costa-Carvalho, G. Riemekasten, T. Torgerson, H.D. Ochs, A. Condino-Neto
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> CD40 ligand (CD40L) deficiency predisposes to opportunistic infections including those caused by fungi and intracellular bacteria. Studies of CD40L-deficient patients reveal the critical role of CD40L-CD40 interaction for the function of T, B, and dendritic cells. However, the consequences of CD40L deficiency on macrophage function remain poorly understood. <h3>Objectives</h3> To analzye the role of CD40L-CD40 interaction in macrophages immune response. <h3>Methods</h3> MDMs were challenged with <i>Paracoccidioides brasiliensis</i> (Pb18, a highly virulent isolate) and the microbicidal activity determined by counting colony forming units (CFU). MDMs oxidative burst was measured by luminol-dependent chemiluminescence (LDCL). Supernatants of macrophages treated or untreated with rhIFN-γ or sCD40L were harvested 48 hours after <i>P. brasiliensis</i> or <i>M. tuberculosis</i> incubation and the Cytokine levels were evaluated by luminex. The analysis of <i>M. tuberculosis</i> (H37Rv strain) phagocytosis and proliferation control by MDMs were carried out by CFU counting. Macrophage transcriptome profiles from three CD40L deficient patients and three healthy controls were analyzed by RNAseq. All the experiments were performed before and after IFN-gamma <i>in vitro</i> treatment. <h3>Results</h3> Here we show that macrophages from CD40L-deficient patients exhibit defective fungicidal activity and reduced oxidative burst, which improved in the presence of IFN-γ but not soluble CD40L (sCD40L). In contrast, both IFN-γ and sCD40L ameliorate impaired production of multiple inflammatory cytokines. Comparing the gene expression signature of macrophages from CD40L-deficient patients to that of controls, we identified 109 differentially expressed genes (DEGs). <i>In vitro</i> treatment of macrophages with IFN-γ decreased the number of DEGs to only 11, and similarly affected the expression of 528 non-DEGs (140 genes down-regulated and 388 up-regulated) comparing patients and healthy controls. Finally, the addition of IFN-γ reversed defective control of <i>M. tuberculosis</i> proliferation by patient macrophages. <h3>Conclusions</h3> Our findings demonstrate that absence of CD40L impairs macrophage development and function. In addition, the improvement of macrophage immune responses by IFN-γ suggests this cytokine as a potential new therapeutic option for patients with CD40L deficiency. <h3>Disclosure of Interest</h3> None declared